Table 2.

Logistic regression analysis of risk of toxicity in patients receiving immune checkpoint inhibitors

	All-grade toxicity		≥G3 toxicity
	Univariate	Multivariable	Univariate	Multivariable
Age category
<65 years	1.00 (ref)	1.00 (ref)	1.00 (ref)	1.00 (ref)
65–74 years	1.14 (0.73 to 1.76)	1.27 (0.79 to 2.03)	0.825 (0.47 to 1.45)	0.96 (0.51 to 1.81)
≥75 years	0.88 (0.54 to 1.42)	1.15 (0.70 to 1.91)	0.53 (0.26 to 1.07)	0.73 (0.33 to 1.61)
Primary site
Melanoma	1.00 (ref)	1.00 (ref)	1.00 (ref)	1.00 (ref)
NSCLC	0.79 (0.51 to 1.24)	0.95 (0.59 to 1.53)	0.50 (0.26 to 0.96)	0.79 (0.38 to 1.62)
RCC	1.02 (0.60 to 1.74)	1.50 (0.86 to 2.61)	0.41 (0.18 to 0.95)	0.90 (0.36 to 2.22)
Treatment type
PD-1 inhibitor	1.00 (ref)	1.00 (ref)	1.00 (ref)	1.00 (ref)
Ipilimumab+nivolumab	4.72 (1.36 to 16.39)	5.24 (1.48 to 18.50)	17.94 (6.71 to 47.91)	16.41 (5.88 to 45.84)
Ipilimumab	8.17 (3.18 to 20.96)	8.93 (3.43 to 23.29)	7.73 (4.08 to 14.65)	7.02 (3.53 to 13.96)

OR with 95% CI for toxicity using logistic regression.

NSCLC, non-small cell lung cancer; RCC, renal cell carcinoma.